ADMA Biologics
ADMA
184 hedge funds and large institutions have $782M invested in ADMA Biologics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 71 increasing their positions, 58 reducing their positions, and 25 closing their positions.
3,339% more call options, than puts
Call options by funds: $619K | Put options by funds: $18K
28% more capital invested
Capital invested by funds: $613M → $782M (+$169M)
22% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 58
0.44% more ownership
Funds ownership: 76.1% → 76.53% (+0.44%)
2% less funds holding
Funds holding: 188 → 184 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.9M |
| 2 |
Morgan Stanley
New York
|
+$8.62M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$8.36M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$7.11M |
| 5 |
BlackRock
New York
|
+$4.66M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.5M |
| 2 |
ACM
Altium Capital Management
New York
|
-$6.02M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.03M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.91M |
| 5 |
FAM
Fred Alger Management
New York
|
-$3.5M |
ADMA Hedge Fund Activity: Q4 2023 in Review
184 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2023, worth a combined $782M — up 28% from $613M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ADMA and 21 opened new positions — a net loss of 4 holders — while 58 trimmed existing stakes and 71 added.
The largest buyer was Deutsche Bank, adding an estimated $10.9M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $13.5M sold.
- 184 institutional investors held ADMA Biologics (ADMA) as of Q4 2023, down from 188 in Q3 2023.
- Funds reported $782M of ADMA Biologics stock for Q4 2023, up 28% quarter-over-quarter.
- 21 funds opened new ADMA Biologics positions in Q4 2023 and 25 closed out, a net change of -4 holders.
- The largest ADMA Biologics buyer in Q4 2023 was Deutsche Bank, an estimated $10.9M added.
- The largest ADMA Biologics seller in Q4 2023 was Adage Capital Partners, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2023.